Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:33 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 543595 | NSE: EPBIO

EP Biocomposites Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹83.51Fairly Valued by 3.57%vs CMP ₹86.60

P/E (15.8) × ROE (10.2%) × BV (₹63.50) × DY (2.00%)

₹135.69Undervalued by 56.69%vs CMP ₹86.60
MoS: +36.2% (Strong)Confidence: 48/100 (Moderate)Models: 1 Under, 3 Fair, 5 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹79.7922%Fair (-7.9%)
Graham NumberEarnings₹88.4816%Fair (+2.2%)
Earnings PowerEarnings₹26.3111%Over (-69.6%)
DCFCash Flow₹32.5713%Over (-62.4%)
Net Asset ValueAssets₹63.357%Over (-26.8%)
EV/EBITDAEnterprise₹90.229%Fair (+4.2%)
Earnings YieldEarnings₹54.807%Over (-36.7%)
ROCE CapitalReturns₹853.079%Under (+885.1%)
Revenue MultipleRevenue₹71.245%Over (-17.7%)
Consensus (9 models)₹135.69100%Undervalued
Key Drivers: Wide model spread (₹26–₹853) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -4.4%

*Investments are subject to market risks

Investment Snapshot

61
EP Biocomposites Ltd scores 61/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health72/100 · Strong
ROCE 14.3% GoodROE 10.2% AverageD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 70.1% Stable
Earnings Quality40/100 · Moderate
OPM stable around 14% SteadyWorking capital: 271 days Capital intensive
Quarterly Momentum90/100 · Strong
Revenue (4Q): +37% YoY AcceleratingProfit (4Q): +51% YoY Strong
Industry Rank40/100 · Moderate
P/E 15.8 vs industry 22.4 In-lineROCE 14.3% vs industry 21.1% AverageROE 10.2% vs industry 35.2% Below peers3Y sales CAGR: 14% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:33 am

Market Cap 14.6 Cr.
Current Price 86.6
Intrinsic Value₹135.69
High / Low 150/75.5
Stock P/E15.8
Book Value 63.5
Dividend Yield0.00 %
ROCE14.3 %
ROE10.2 %
Face Value 10.0
PEG Ratio-3.55

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for EP Biocomposites Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
EP Biocomposites Ltd 14.6 Cr. 86.6 150/75.515.8 63.50.00 %14.3 %10.2 % 10.0
Antony Waste Handling Cell Ltd 1,148 Cr. 404 693/37217.7 2430.00 %12.1 %11.3 % 5.00
Eco Recycling Ltd 590 Cr. 306 724/22533.6 52.50.00 %36.8 %84.0 % 10.0
Industry Average869.00 Cr265.5322.37119.670.00%21.07%35.17%8.33

All Competitor Stocks of EP Biocomposites Ltd

Quarterly Result

MetricSep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Sales 2.765.303.453.684.407.044.407.604.07
Expenses 2.424.272.923.264.145.903.916.313.82
Operating Profit 0.341.030.530.420.261.140.491.290.25
OPM % 12.32%19.43%15.36%11.41%5.91%16.19%11.14%16.97%6.14%
Other Income 0.000.010.030.130.090.210.050.060.07
Interest 0.020.130.150.050.010.020.170.190.15
Depreciation 0.010.060.050.050.050.050.050.060.05
Profit before tax 0.310.850.360.450.291.280.321.100.12
Tax % 25.81%32.94%25.00%33.33%27.59%27.34%34.38%25.45%33.33%
Net Profit 0.240.570.270.300.220.930.210.830.09
EPS in Rs 2.044.841.611.781.315.531.254.940.54

Last Updated: December 27, 2025, 2:06 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 3:46 am

MetricMar 2020n n 3mMar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 0.572.958.067.1211.4312.0111.67
Expenses 0.532.496.666.1510.0210.2310.13
Operating Profit 0.040.461.400.971.411.781.54
OPM % 7.02%15.59%17.37%13.62%12.34%14.82%13.20%
Other Income 0.000.000.020.170.300.110.13
Interest 0.000.000.190.230.040.360.34
Depreciation 0.000.000.070.100.100.110.11
Profit before tax 0.040.461.160.811.571.421.22
Tax % 25.00%23.91%31.03%28.40%26.75%27.46%
Net Profit 0.030.360.810.581.151.030.92
EPS in Rs 6.0072.006.883.456.846.135.48
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)125.00%-28.40%98.28%-10.43%
Change in YoY Net Profit Growth (%)0.00%-153.40%126.67%-108.71%

EP Biocomposites Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:84%
3 Years:14%
TTM:5%
Compounded Profit Growth
10 Years:%
5 Years:103%
3 Years:8%
TTM:-10%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:%
1 Year:-21%
Return on Equity
10 Years:%
5 Years:15%
3 Years:11%
Last Year:10%

Last Updated: September 5, 2025, 3:26 pm

Balance Sheet

Last Updated: December 4, 2025, 2:50 am

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 0.050.051.181.681.681.681.68
Reserves -0.020.340.826.737.888.919.00
Borrowings 0.000.004.111.281.802.983.69
Other Liabilities 0.520.943.162.033.723.061.43
Total Liabilities 0.551.339.2711.7215.0816.6315.80
Fixed Assets 0.000.000.410.330.330.230.20
CWIP 0.000.000.000.000.140.140.15
Investments 0.000.000.000.000.000.000.00
Other Assets 0.551.338.8611.3914.6116.2615.45
Total Assets 0.551.339.2711.7215.0816.6315.80

Reserves and Borrowings Chart

Cash Flow

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0.120.03-4.28-0.79-1.24-0.49
Cash from Investing Activity + 0.000.00-0.470.02-0.160.02
Cash from Financing Activity + 0.000.004.762.810.490.82
Net Cash Flow 0.120.030.012.04-0.920.35
Free Cash Flow 0.120.03-4.75-0.81-1.48-0.50
CFO/OP 300%9%-294%-44%-59%-1%

Free Cash Flow

MonthMar 2020n n 3mMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow0.040.46-2.71-0.31-0.39-1.20

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 192.1180.42321.53300.41287.40330.05
Inventory Days 83.6590.2586.8390.5853.8666.66
Days Payable 349.79128.35161.90104.79153.7497.87
Cash Conversion Cycle -74.0442.32246.47286.20187.52298.85
Working Capital Days -57.6325.98156.69255.81217.47270.79
ROCE %219.05%41.54%13.16%15.30%14.20%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2022Mar 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 69.31%70.08%70.08%70.08%70.08%70.08%70.08%70.08%70.08%70.08%70.05%70.08%
FIIs 1.19%2.20%2.20%2.20%2.20%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public 29.49%27.72%27.71%27.71%27.72%29.92%29.92%29.92%29.92%29.92%29.95%29.92%
No. of Shareholders 249252315329339374365365382374361356

Shareholding Pattern Chart

No. of Shareholders

EP Biocomposites Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 6.136.843.949.486.97
Diluted EPS (Rs.) 6.136.843.949.486.97
Cash EPS (Rs.) 6.807.444.027.4371.66
Book Value[Excl.RevalReserv]/Share (Rs.) 63.0156.8850.0416.9777.30
Book Value[Incl.RevalReserv]/Share (Rs.) 63.0156.8850.0416.9777.30
Revenue From Operations / Share (Rs.) 71.4068.0342.4168.45589.60
PBDIT / Share (Rs.) 11.2010.156.6411.7992.90
PBIT / Share (Rs.) 10.549.556.0511.2392.84
PBT / Share (Rs.) 8.439.344.849.9092.84
Net Profit / Share (Rs.) 6.136.843.436.8771.60
PBDIT Margin (%) 15.6914.9115.6517.2215.75
PBIT Margin (%) 14.7514.0314.2616.4015.74
PBT Margin (%) 11.8013.7211.4114.4615.74
Net Profit Margin (%) 8.5810.048.0710.0412.14
Return on Networth / Equity (%) 9.7212.026.8440.5092.62
Return on Capital Employeed (%) 13.5715.0410.5431.51120.10
Return On Assets (%) 6.197.624.918.7227.04
Long Term Debt / Equity (X) 0.230.110.141.090.00
Total Debt / Equity (X) 0.280.180.152.060.00
Asset Turnover Ratio (%) 0.750.850.671.523.14
Current Ratio (X) 3.952.844.451.691.39
Quick Ratio (X) 3.552.603.961.460.90
Inventory Turnover Ratio (X) 9.826.053.566.986.39
Interest Coverage Ratio (X) 5.3148.885.508.890.00
Interest Coverage Ratio (Post Tax) (X) 3.9133.943.846.180.00
Enterprise Value (Cr.) 22.1123.5932.970.000.00
EV / Net Operating Revenue (X) 1.842.064.620.000.00
EV / EBITDA (X) 11.7413.8329.530.000.00
MarketCap / Net Operating Revenue (X) 1.732.024.750.000.00
Price / BV (X) 1.962.414.030.000.00
Price / Net Operating Revenue (X) 1.732.024.750.000.00
EarningsYield 0.040.040.010.000.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

EP Biocomposites Ltd. is a Public Limited Listed company incorporated on 17/06/2020 and has its registered office in the State of Goa, India. Company's Corporate Identification Number(CIN) is U28900GA2020PLC014240 and registration number is 014240. Currently company belongs to the Industry of Waste Management. Company's Total Operating Revenue is Rs. 12.01 Cr. and Equity Capital is Rs. 1.68 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Waste ManagementD-2/12, Bicholim Industrial Estate, Bicholim Goa 403504Contact not found
Management
NamePosition Held
Mr. Rajkumar Gajanan KamatManaging Director
Mr. Shreyas Dattatray NadkarniDirector
Ms. Leena KamatDirector
Mr. Nitin Anant KunkolienkerIndependent Director
Mr. Dinesh Naguesh ShenoyIndependent Director

FAQ

What is the intrinsic value of EP Biocomposites Ltd and is it undervalued?

As of 09 April 2026, EP Biocomposites Ltd's intrinsic value is ₹135.69, which is 56.69% higher than the current market price of ₹86.60, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (10.2 %), book value (₹63.5), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of EP Biocomposites Ltd?

EP Biocomposites Ltd is trading at ₹86.60 as of 09 April 2026, with a FY2026-2027 high of ₹150 and low of ₹75.5. The stock is currently near its 52-week low. Market cap stands at ₹14.6 Cr..

How does EP Biocomposites Ltd's P/E ratio compare to its industry?

EP Biocomposites Ltd has a P/E ratio of 15.8, which is below the industry average of 22.37. This is broadly in line with or below the industry average.

Is EP Biocomposites Ltd financially healthy?

Key indicators for EP Biocomposites Ltd: ROCE of 14.3 % is moderate. Dividend yield is 0.00 %.

Is EP Biocomposites Ltd profitable and how is the profit trend?

EP Biocomposites Ltd reported a net profit of ₹1 Cr in Mar 2025 on revenue of ₹12 Cr. Compared to ₹1 Cr in Mar 2022, the net profit shows an improving trend.

Does EP Biocomposites Ltd pay dividends?

EP Biocomposites Ltd has a dividend yield of 0.00 % at the current price of ₹86.60. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in EP Biocomposites Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports